SB
SURF

Samsara BioCapital’s Surface Oncology, Inc. Common Stock SURF Stock Holding History

Samsara BioCapital’s Portfolio SURF Stock Details SURF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-78,300
Closed -$221K – 21
2019
Q2 		$221K Hold
78,300
– – 0.15% 19
2019
Q1 		$373K Hold
78,300
– – 0.29% 16
2018
Q4 		$332K Buy
+78,300
New +$605K 0.32% 15

Other funds holding SURF

AVAI
Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Samsara BioCapital's SURF Position: Q3 2019 in Review

Samsara BioCapital sold out of Surface Oncology, Inc. Common Stock (SURF) in Q3 2019, closing a stake of 78,300 shares — an estimated $221K sold.

Samsara BioCapital first reported a position in SURF in Q4 2018 and held it in 3 quarters. The position peaked at $373K in Q1 2019. 35 funds tracked by Wall St. Rank hold SURF as of Q3 2019.

  • Samsara BioCapital reported no remaining Surface Oncology, Inc. Common Stock position as of Q3 2019 after selling out during the quarter.
  • Samsara BioCapital sold 78,300 Surface Oncology, Inc. Common Stock shares in Q3 2019, an estimated $221K.
  • Samsara BioCapital first reported a position in Surface Oncology, Inc. Common Stock in Q4 2018 and held it in 3 quarters.
  • Samsara BioCapital's Surface Oncology, Inc. Common Stock position peaked at $373K in Q1 2019.
  • 35 funds tracked by Wall St. Rank held Surface Oncology, Inc. Common Stock as of Q3 2019.

Based on Samsara BioCapital's 13F filing for Q3 2019, filed 14 Nov 2019.